This article first appeared on GuruFocus .
-
Normalized FFO:$39 million, or $0.16 per share.
-
Adjusted EBITDA RE:$82 million.
-
Consolidated NOI:Increased 20.4% year-over-year to $84 million.
-
SHOP Same-Property NOI:Increased 37.2% year-over-year to $52 million.
-
SHOP Same-Property Occupancy:Increased 160 basis points year-over-year to 83.1%.
-
SHOP Average Monthly Rate:Increased 6.2% year-over-year.
-
Medical Office and Life Science Same-Property Occupancy:Increased 110 basis points year-over-year to 95.8%.
-
Medical Office and Life Science Same-Property NOI:$24.1 million, essentially flat year-over-year.
-
Leasing Activity:Approximately 477,000 square feet of new and renewal leasing at a 6.7% rent rollup.
-
Liquidity:Approximately $267 million at quarter end.
-
Net Debt to Adjusted EBITDA RE:7.1 times, down from 8.7 times in the prior year.
-
Adjusted EBITDA RE to Interest Expense:Improved to 2.2 times from 1.4 times in the prior year.
-
G&A Expense:$7.1 million for the quarter, excluding a $10 million incentive management fee and $2.3 million of non-cash share-based compensation.
-
Capital Expenditures:$25.8 million invested in the quarter, including $19.1 million in SHOP communities and $6.7 million in medical office and life science portfolio.
Release Date: August 04, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Diversified Healthcare Trust ( NASDAQ:DHC ) reported strong second quarter results, with normalized FFO of $39 million and consolidated NOI increasing 20.4% year-over-year, exceeding analyst estimates.
-
SHOP segment same-property NOI surged 37.2% year-over-year, driven by a 160 basis point occupancy increase, a 6.2% rise in average monthly rate, and continued margin expansion.
-
The company is renegotiating legacy operator contracts to align with a more favorable fee structure, expected to deliver immediate annual cost savings of nearly $2 million starting in January 2027.
-
DHC is executing a $20 million repositioning plan to convert closed skilled nursing wings into high-demand senior housing units, projected to generate mid-teens unlevered returns and add roughly 150 units.
-
Leverage improved significantly, with net debt to EBITDA down to 7.1 times from 8.7 times year-over-year, and liquidity stands at $267 million, providing financial flexibility.
-
The company reaffirmed its full-year guidance, with SHOP NOI tracking towards the high end, supported by expense synergies such as new food and beverage contracts yielding $14-16 million in annualized savings.
Negative Points
-
SHOP occupancy growth is pacing below initial 2026 projections, with average occupancy growth guidance reduced by 100 basis points to 200 basis points, reflecting a slower-than-expected ramp-up.
-
Revenue growth in the SHOP segment was revised down by 140 basis points to 6.6%, indicating top-line momentum is temporarily muted due to transition-related disruptions.
-
The company noted a one-time benefit of $1.5 million in Q2 SHOP NOI from expense timing that will not repeat in Q3, potentially impacting sequential performance.
-
Medical office and life science segment NOI was essentially flat year-over-year, with known tenant vacates representing 4.6% of annualized revenue, including two that vacated in July.
-
G&A expenses included a $10 million incentive management fee and $2.3 million in non-cash share-based compensation, with over half of the latter being a one-time accelerated vesting expense.
-
The company faces ongoing challenges in fully integrating new operators, with sales teams and infrastructure still being rebuilt, which has delayed occupancy gains.
Q & A Highlights
Q: Can you provide additional color on why the SHOP topline is tracking below expectations, and is this mainly driven by a slower leasing season or something more temporary? A: Christopher Bilotto, President and CEO, attributed the slower pace to "transition noise" from operator changes. New operators have spent the last six months rebuilding local leadership and sales teams. These teams are now largely in place, and benefits are starting to flow through, but the pace of occupancy growth is expected to be somewhat muted in the near term. He remains bullish on the long-term outlook for driving occupancy.
Q: Is the lower RevPAR driven by the occupancy uptick, or did you have to be more judicious on increasing rates for existing residents due to the transitions? A: CEO Christopher Bilotto clarified that total RevPOR is actually increasing. The decrease in total revenue is tied to occupancy levels. The company is seeing strong uptake in ancillary revenues and higher acuity care levels, which is driving outsized results in RevPOR. As occupancy ramps, they expect to recapture the incremental revenue.
Q: On the expense side, is the benefit from new group contracts a good baseline going forward, or is there more benefit moving into 2017? A: CFO Matthew Brown stated that the new guidance is a good run rate for the end of this year. However, they expect additional synergies moving into 2027, both from new operators and from expected changes to legacy operator management contracts. For 2026, they are seeing significant savings in dietary, maintenance, and contract labor.
Q: Regarding the new management agreements starting in 2027, are there opportunities for additional agreement changes longer-term, or does this encompass the entire portfolio? A: CEO Christopher Bilotto confirmed that once these new agreements are in place, they will encompass the entire portfolio, covering the balance of 80-plus communities outside of the Aleris transition. He does not anticipate major changes to the contracts in the near term, though they are evaluating other opportunities related to operators.
Q: Can you provide color on the $1.5 million of one-time expense benefits in the quarter that won't roll forward? A: CFO Matthew Brown explained that it was due to the timing of expense recognition, specifically over-accruals in the first quarter that were offset in the second quarter.
Q: Given the strong 1H SHOP NOI performance, are you tracking towards the high end of guidance, and is there any seasonality to be aware of in 3Q or 4Q? A: CFO Matthew Brown confirmed they are tracking to the high end of guidance. They expect a little bit of seasonality in the third quarter related to increases in utilities, but nothing overly material. Overall, they feel good about the high end of the guidance.
Q: You've already achieved a rate growth of close to 6% in 1H, but guidance is 5.5% for the full year. Any reason not to raise that further? A: CEO Christopher Bilotto stated they are comfortable with the current trajectory and are being mindful of the many moving pieces related to transitions. He believes there is a reasonable expectation to continue the run rate into 2027 with consistent growth across the portfolio.
Q: Is the lower occupancy guidance a result of new operators not chasing expensive occupancy, or is it just a timing issue? A: CEO Christopher Bilotto indicated it is a timing issue, not a lack of focus on top-line growth. The guidance reflects average occupancy growth for the year, and they still feel good about real growth by year-end. There are also other upsides from levels of care and ancillary revenue that will continue to drive performance.
Q: What drove the quarter-over-quarter decline in MOB Life Science rental revenue? A: CFO Matthew Brown noted there was a one-time bad debt charge of about $1 million impacting Q2 results. This was unrelated to the upcoming vacancies.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
